Incidence and predictors of 2-year mortality following percutaneous left atrial appendage occlusion in the EWOLUTION trial
Europace · 02.07.2024 · 26 (7)
DOI: 10.1093/europace/euae188 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Europace, online erschienen am 31.07.2024. Verfasst von Errol W Aarnink und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, St Antonius Ziekenhuis Nieuwegein/AUMC Amsterdam, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands. Hauptthemen laut MEDLINE: Atrial Appendage, Atrial Fibrillation, Registries, Stroke. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boston Scientific Corporation.
Abstract (Originalsprache)
Aims
Sufficient survival time following left atrial appendage occlusion (LAAO) is essential for ensuring the efficacy and cost-effectiveness of this strategy for stroke prevention. Understanding prognostic factors for early mortality after LAAO could optimize patient selection. In the current study, we perform an in-depth analysis of 2-year mortality after LAAO, focusing particularly on potential predictors. Methods and results The EWOLUTION registry is a real-world cohort comprising 1020 patients that underwent LAAO. Endpoint definitions were pre-specified, and death was categorized as cardiovascular, non-cardiovascular, or unknown origin. Mortality rates were calculated from Kaplan–Meier estimates. Baseline characteristics significantly associated with death in univariate Cox regression analysis were incorporated into the multivariate analysis. All multivariate predictors were included in a risk model. Two-year mortality rate was 16.4% [confidence interval (CI): 14.0–18.7%], with 50% of patients dying from a non-cardiovascular cause. Multivariate baseline predictors of 2-year mortality included age [hazard ratio (HR) 1.05, CI: 1.03–1.08, per year increase], heart failure (HR 1.73, CI: 1.24–2.41), vascular disease (HR 1.47, CI: 1.05–2.05), valvular disease (HR 1.63, CI: 1.15–2.33), abnormal liver function (HR 1.80, CI: 1.02–3.17), and abnormal renal function (HR 1.58, CI: 1.10–2.27). Mortality rate exhibited a gradual rise as the number of risk factors increased, reaching 46.1% in patients presenting with five or six risk factors.
Conclusion
One in six patients died within 2 years after LAAO. We identified six independent predictors of mortality. When combined, this model showed a gradual increase in mortality rate with a growing number of risk factors, which may guide appropriate patient selection for LAAO. Clinical trial registration The original EWOLUTION registry was registered at clinicaltrials.gov under identifier NCT01972282.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, St Antonius Ziekenhuis Nieuwegein/AUMC Amsterdam, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands.
- Department of Cardiology, Vivantes Klinikum Am Urban and Neukölln, Berlin, Germany.
- Department of Cardiology, Universitätsmedizin Rostock, Rostock, Germany.
- Department of Cardiology, Vivantes Klinikum im Friedrichshain, Berlin, Germany.
- State Research Institute of Circulation Pathology, Novosibirsk, Russia.
- Department of Cardiology, Elisabeth Krankenhaus Essen, Essen, Germany.
ORCID-Profile: Errol W Aarnink, Evgeny Pokushalov, Boris Schmidt, Felix Meincke, Alexey Vladimir Protopopov, Timothy Betts, Patrizio Mazzone, Marek Grygier, Tom De Potter, Elisa Vireca, Martin W Bergmann, Lucas V A Boersma
Förderung
- Boston Scientific Corporation
Zitieren
APA
Aarnink, E. W., Ince, H., Kische, S., Pokushalov, E., Schmitz, T., Schmidt, B., Gori, T., Meincke, F., Protopopov, A. V., Betts, T., Mazzone, P., Grygier, M., Sievert, H., De Potter, T., Vireca, E., Stein, K., Bergmann, M. W., & Boersma, L. V. A. (2024). Incidence and predictors of 2-year mortality following percutaneous left atrial appendage occlusion in the EWOLUTION trial. Europace, 26(7). https://doi.org/10.1093/europace/euae188
Vancouver
Aarnink EW, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, et al. Incidence and predictors of 2-year mortality following percutaneous left atrial appendage occlusion in the EWOLUTION trial. Europace. 2024;26(7). doi:10.1093/europace/euae188
BibTeX
@article{Aarnink2024,
author = {Aarnink, Errol W and Ince, Hueseyin and Kische, Stephan and Pokushalov, Evgeny and Schmitz, Thomas and Schmidt, Boris and Gori, Tommaso and Meincke, Felix and Protopopov, Alexey Vladimir and Betts, Timothy and Mazzone, Patrizio and Grygier, Marek and Sievert, Horst and De Potter, Tom and Vireca, Elisa and Stein, Kenneth and Bergmann, Martin W and Boersma, Lucas V A},
title = {Incidence and predictors of 2-year mortality following percutaneous left atrial appendage occlusion in the EWOLUTION trial},
journal = {Europace},
year = {2024},
volume = {26},
number = {7},
doi = {10.1093/europace/euae188}
}
EUVIMED